• Journal Article

Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations

Citation

Graham, J., Earnshaw, S., Lim, J., Luthra, R., & Borker, R. (2016). Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations. Journal of Clinical Pathways, 2(4), 31-39.

Abstract